Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
RPL-301 by Rocket Pharmaceuticals for Anemia: Likelihood of Approval
RPL-301 is under clinical development by Rocket Pharmaceuticals and currently in Phase I for Anemia. According to GlobalData, Phase I...
Data Insights
Risk adjusted net present value: What is the current valuation of Rocket Pharmaceuticals's RPL-301?
RPL-301 is a gene-modified cell therapy commercialized by Rocket Pharmaceuticals, with a leading Phase I program in Anemia. According to...